Nectar Lifesciences Limited (NECLIFE.NS)
INR 24.43
(-5.02%)
INR 24.43
(-5.02%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.4 Billion INR | -38.05% |
| 2022 | 2.26 Billion INR | -22.19% |
| 2021 | 2.91 Billion INR | 126.98% |
| 2020 | 1.28 Billion INR | 5.56% |
| 2019 | 1.21 Billion INR | -26.64% |
| 2018 | 1.65 Billion INR | -24.76% |
| 2017 | 2.2 Billion INR | 34.36% |
| 2016 | 1.63 Billion INR | -33.25% |
| 2015 | 2.45 Billion INR | -7.58% |
| 2014 | 2.65 Billion INR | 18.89% |
| 2013 | 2.23 Billion INR | -14.42% |
| 2012 | 2.6 Billion INR | -28.23% |
| 2011 | 3.63 Billion INR | -54.32% |
| 2010 | 7.95 Billion INR | 32.47% |
| 2009 | 6 Billion INR | -14.69% |
| 2008 | 7.04 Billion INR | 45.28% |
| 2007 | 4.84 Billion INR | 14.85% |
| 2006 | 4.22 Billion INR | 157.14% |
| 2005 | 1.64 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 1.83 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.4 Billion INR | 0.0% |
| 2023 FY | 1.4 Billion INR | -38.05% |
| 2022 Q2 | 2.57 Billion INR | 0.0% |
| 2022 Q4 | 2.26 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 2.26 Billion INR | -22.19% |
| 2021 Q4 | 2.91 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.91 Billion INR | 126.98% |
| 2021 Q2 | 3.1 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.28 Billion INR | 5.56% |
| 2020 Q2 | 1.22 Billion INR | 0.0% |
| 2020 Q4 | 1.28 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 1.21 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 1.21 Billion INR | -26.64% |
| 2019 Q2 | 1.22 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 1.65 Billion INR | 0.0% |
| 2018 FY | 1.65 Billion INR | -24.76% |
| 2017 FY | 2.2 Billion INR | 34.36% |
| 2016 FY | 1.63 Billion INR | -33.25% |
| 2015 FY | 2.45 Billion INR | -7.58% |
| 2014 FY | 2.65 Billion INR | 18.89% |
| 2013 FY | 2.23 Billion INR | -14.42% |
| 2012 FY | 2.6 Billion INR | -28.23% |
| 2011 FY | 3.63 Billion INR | -54.32% |
| 2010 FY | 7.95 Billion INR | 32.47% |
| 2009 FY | 6 Billion INR | -14.69% |
| 2008 FY | 7.04 Billion INR | 45.28% |
| 2007 FY | 4.84 Billion INR | 14.85% |
| 2006 FY | 4.22 Billion INR | 157.14% |
| 2005 FY | 1.64 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aarti Drugs Limited | 2.75 Billion INR | 49.04% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -350671.75% |
| Albert David Limited | 6.01 Million INR | -23222.59% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | -123.137% |
| Bafna Pharmaceuticals Limited | 107.53 Million INR | -1204.809% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| FDC Limited | 2.46 Million INR | -56797.283% |
| Gufic Biosciences Limited | 1.53 Billion INR | 8.869% |
| Hikal Limited | 4.22 Billion INR | 66.818% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -1156.954% |
| Ind-Swift Limited | 10.09 Billion INR | 86.101% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 95.57% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -950.679% |
| Medico Remedies Limited | 8.67 Million INR | -16079.509% |
| Morepen Laboratories Limited | 33.64 Million INR | -4070.889% |
| Orchid Pharma Limited | 1.2 Billion INR | -16.507% |
| Procter & Gamble Health Limited | 68.8 Million INR | -1939.371% |
| RPG Life Sciences Limited | -30.3 Million INR | 4730.65% |
| Alembic Limited | 73.9 Million INR | -1798.629% |
| Alkem Laboratories Limited | 400 Million INR | -250.772% |
| Bajaj HealthCare Limited | 650.34 Million INR | -115.745% |
| Brooks Laboratories Limited | 3.56 Million INR | -39257.279% |
| Eris Lifesciences Limited | 6.54 Billion INR | 78.563% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -850.537% |
| Sigachi Industries Limited | 265.79 Million INR | -427.877% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | -19.473% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -10449.526% |
| Innova Captab Limited | 2.1 Billion INR | 33.351% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -560.724% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -1756.672% |
| Themis Medicare Limited | 267.74 Million INR | -424.048% |
| Unichem Laboratories Limited | 382.22 Million INR | -267.088% |
| Vaishali Pharma Limited | 35.98 Million INR | -3799.305% |
| Venus Remedies Limited | 386.8 Million INR | -262.742% |
| Wanbury Limited | 820 Million INR | -71.108% |
| Windlas Biotech Limited | 20.18 Million INR | -6852.859% |
| ZIM Laboratories Limited | 356 Million INR | -294.119% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Lupin Limited | 1.55 Billion INR | 9.641% |
| Sakar Healthcare Limited | 549.55 Million INR | -155.316% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 93.428% |
| Divi's Laboratories Limited | 20 Million INR | -6915.435% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -4940.548% |
| Mankind Pharma Limited | 325.81 Million INR | -330.639% |
| Sequent Scientific Limited | 1.42 Billion INR | 1.689% |
| Laurus Labs Limited | 7.98 Billion INR | 82.423% |
| Neuland Laboratories Limited | 449.2 Million INR | -212.348% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -493.522% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 7.504% |
| Zydus Lifesciences Limited | 251 Million INR | -458.999% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -9945.01% |
| Wockhardt Limited | 8.91 Billion INR | 84.253% |
| Bal Pharma Limited | 363.82 Million INR | -285.65% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 76.576% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -294.212% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -15150.946% |
| Shilpa Medicare Limited | 5.6 Billion INR | 74.952% |
| Valiant Laboratories Limited | 750.89 Million INR | -86.854% |
| Ajanta Pharma Limited | 235.2 Million INR | -496.551% |
| Hester Biosciences Limited | 1.81 Billion INR | 22.811% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -4251.499% |
| Granules India Limited | 689.71 Million INR | -103.431% |
| Medicamen Biotech Limited | 12.55 Million INR | -11075.524% |
| Ipca Laboratories Limited | 5.8 Billion INR | 75.826% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 115201.477% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.738% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 91.253% |
| NATCO Pharma Limited | 53 Million INR | -2547.334% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 23.537% |
| Strides Pharma Science Limited | 6.71 Billion INR | 79.105% |
| Indoco Remedies Limited | 3.51 Billion INR | 60.109% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -1216.217% |